

CLS SCIENTIFIC PROGRAMME

Please note the program below is subject to change.

* GL = Guest Lecture

Monday, April 25, 2016

Acute Lymphoblastic Leukemia - Novel findings in disease characteristics

08:30 - 10:00, Banqueting Hall

- 01 CRLF2 Over-expression is a poor prognostic marker in children with high risk T cell Acute lymphoblastic leukemia
Palmi, Chiara (Italy)
- 02 Towards RNA-based Next Generation Sequencing Target capture for research and clinical diagnostics in childhood B-Cell precursor Acute lymphoblastic leukemia
Fazio, Grazia (Italy)
- 03 A refined diagnostic strategy for the efficient and comprehensive assessment of clinical relevant genetic alterations in childhood ALL
Nebral, Karin (Austria)
- 04 Genetic features of High risk B-Cell precursor Acute lymphoblastic Leukemia (BCP-ALL) cases in the Austrian ALL-BFM 2000 and 2009 treatment study
Haslinger, Sabrina (Austria)
- 05 DNA array –based options for identifying gene fusions in childhood ALL
Inthal, Andrea (Austria)
- 06 Predictive value of MRD in Ph+ ALL treated with Imatinib in the EsPhALL study
Cazzaniga, Gianni (Italy)

Session chairs: Dworzak, Michael & Stiakaki, Eftichia

10:00 - 10:30 Coffee Break

Acute Lymphoblastic Leukemia - New clinical approaches

10:30 - 12:30, Banqueting Hall

- GL 1* **Immune Therapy in childhood acute Leukemia: a long journey ready to start**
Locatelli, Franco (Italy)
- 07 Dexamethasone vs. prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Moericke, Anja (Germany)
- 08 T cell Acute Lymphoblastic Leukemia patients with mutations IL7Ra or

downstream RAS-MEK or PI3K-AKT can be collectively targeted by combination of RAS and AKT inhibitors
Cante-Barret, Kirsten (Netherlands)

- 09 Identification of targetable lesions in children with pB-ALL of the ALL-BFM study group using fluorescence in-situ hybridization and arrayCGH
Goehring, Gudrun (Germany)
- 10 Outcome of very high risk Paediatric Acute Lymphoblastic Leukaemia on a contemporary protocol: Results of the UKALL 2003 Trial
Tan, Ronald (UK)
- 11 Preclinical evaluation of an improved Sleeping beauty Transposon Platform for acute leukemia immunotherapy by Chimeric Antigen Receptor modified lymphocytes
Magnani, Chiara Francesca (Italy)
- 12 A novel chimeric antigen receptor (CAR) specific for the antigen CD19, incorporating the suicide gene inducible Caspase 9, for effective and safe adoptive immunotherapy of patients with B cell ALL
Quintarelli, Concetta (Italy)

Session chairs: *Van den Heuvel-Eibrink, Marry & Baka, Margarita*
Guest lecture 1 chair: *Polychronopoulou, Sophia*

12:30 - 14:00 Lunch Break

AMGEN Satellite Symposia

The evolving role of T-cell engaging immunotherapy in paediatric ALL: an update

12:50 - 13:50, Banqueting Hall

Welcome and introduction

Locatelli, Franco (Italy)

Clinical development of blinatumomab in children: current status

Saha, Vaskar (UK)

Clinical development of CAR-T-cell therapy in children: current status

Quintarelli, Concetta (Italy)

Panel discussion and closing remarks

Panel

Session chair: *Locatelli, Franco (Italy)*

[Click here](#) for details and invitation



AMGEN[®]
Oncology

Acute Myeloid Leukemia, Myelodysplastic Syndromes: Diagnostic and clinical insights

14:00 - 16:00, Banqueting Hall

GL 2* **Mutation landscape in childhood myelodysplastic syndromes : Results from EWOG/MDS**
Wlodarski, Marcin (Germany)

- 13 Development of the treatment and outcome improvement in

childhood acute myeloid leukemia in Poland from 1983 to 2015
Czogala, Malgorzata (Poland)

- 14 Next generation sequencing identifies a novel subset of Non-Down syndrome acute megacaryoblastic Leukemia characterized by chimeric transcripts involving HOX cluster genes
Fornerod, Maarten (Netherlands)
- 15 Balance of Anti-CD123 Chimeric Antigen receptor (CAR) binding affinity and density in an in vitro model of Acute Myeloid Leukemia
Arcangeli, Silvia (Italy)
- 16 B cell deficiency is the most constant feature of GATA-2 deficiency in childhood MDS
Mejstrikova, Ester (Czech Republic)
- GL 3* 25 years of modern therapy of Down's syndrome AML: lessons learned and questions to solve**
Ravindranath, Yaddanapudi (USA)

Session chair: Reinhardt, Dirk

Guest lecture 2 chair: Biondi, Andrea

Guest lecture 3 chair: Kosmidis, Helen V.

Poster Session

16:00 - 18:30, Banqueting Hall Foyer

[Click here](#) to see the list of posters.

Session chairs: Conter, Valentino & Campbell, Myriam

Tuesday, April 26, 2016

Acute Leukemia: Novel diagnostic findings

08:30 - 10:15, Banqueting Hall

- GL 4* The Genomic Landscape of Pediatric mixed Phenotype Acute Leukemia**
Alexander, Thomas (USA)
- 17 Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with Pegylated Asparaginase in the Induction phase (protocol I) of the AIEOP-BFM ALL 2009 trial
Rizzari, Carmelo (Italy)
- 18 CNOT1 and mir-1206 micro RNA variants are associated with Methotrexate induced toxicity in pediatric acute lymphoblastic leukemia
Oosterom, Natanja (Netherlands)
- 19 Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and impact relapse risk in childhood acute lymphoblastic leukemia
van Leeuwen, Frank (Netherlands)
- 20 Mixed phenotype acute leukemia (MPAL): biological profile clinical characteristics and treatment outcomes - an experience of the Polish Pediatric leukemia/Lymphoma Study Group (PPLLSG)
Konatkowska, Benigna (Poland)

- 21 The histone deacetylase inhibitor Givinostat (ITF2357) has a potent antitumor activity against CRLF2-rearranged B cell precursor acute lymphoblastic leukemia
Savino, Angela-Maria (Italy)

Session chairs: Hasle, Henrik & Kattamis, Antonis

Guest lecture 4 chair: Schrappe, Martin

10:15 - 10:45 Coffee Break

Refractory Leukemia and Miscellaneous

10:45 - 12:45, Banqueting Hall

- 22 Australian Children with Ph-like Acute lymphoblastic Leukemia enrolled on ANZCHOG ALL8 had a high prevalence of relapse despite risk adapted treatment
White, Deborah (Australia)
- 23 Flow cytometry in IntReALL protocol. Validation and standardization of flow cytometric minimal residual disease and CD22 expression analysis
Mejstrikova, Ester (Czech Republic)
- 24 Lack of BCR-ABL1 mutations and clonal evolution dynamics in pediatric Ph+ ALL patients resistant/refractory to Imatinib treatment
Cazzaniga, Gianni (Italy)
- 25 Involvement of the central nervous system in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor providing a novel target for directed therapy
Meyer, Lueder-Hinrich (Germany)
- 26 An Fc-engineered CD 19 antibody is active in preclinical mouse models of acute lymphoblastic leukemia (ALL) minimal residual disease by engagement of myeloid effector cells
Schewe, Denis (Germany)
- 27 Antileukemic activity of the DNA methyltransferase inhibitor azacitidine in a xenograft model of juvenile myelomonocytic leukemia
Krombholz, Christopher Felix (Germany)
- 28 Genomic landscape of relapsed Acute lymphoblastic leukemia
Waanders, Esme (Netherlands)
- 29 Gene expression analysis of sequential stages of in vitro T-Cell differentiation reveals that Human T cell commitment occurs prior to the CD1a+ stage
Cante-Barrett, Kirsten (Netherlands)

Session chair: Pourtsidis, Apostolos & Felice, Marisa